



## Tarceva<sup>®</sup> (erlotinib) – First-time generic

- On May 9, 2019, [Teva launched AB-rated](#) generic versions of Genentech's [Tarceva \(erlotinib\)](#) 100 mg and 150 mg tablets, and [Mylan launched AB-rated](#) generic versions of Tarceva 25 mg, 100 mg, and 150 mg tablets.
- Tarceva is indicated for:
  - Treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.
  - In combination with [gemcitabine](#) for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
- According to IQVIA data as of March 2019, Tarceva had annual sales of \$212 million in the U.S.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.